Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies
Stopped early · Phase 1
Conditions studied: Squamous Cell Carcinoma of Head and Neck
In brief
There are two main goals of this study: The first is to find the highest safe dose of REGN6569 when given with cemiplimab. The second is to get some initial information about how well the REGN6569 in combination with cemiplimab may help shrink certain types of cancer. The study is also looking at: * Side effects that may be experienced by people taking REGN6569 alone and with cemiplimab * How REGN6569 and cemiplimab work in the body * How much REGN6569 and cemiplimab is in your blood * To see if REGN6569 can lower the number of Treg cells in tumors * To see if REGN6569 and cemiplimab can shrink tumors when given together
Key facts
- Study ID
- NCT04465487
- Run by
- Regeneron Pharmaceuticals
- People needed
- 38
- Starts
- 2020-10-05
- Expected to finish
- 2025-02-07
- Last updated by the study team
- 2025-02-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Angeles Clinic and Research Institute - Clinic/Outpatient Facility — Los Angeles, California, United States
- H.Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
- University of Michigan — Ann Arbor, Michigan, United States
- START South Texas Accelerated Research Therapeutics — Grand Rapids, Michigan, United States
- Hospital Universitario Vall d'Hebrón — Barcelona, Spain
- ICO l'Hospitalet - Hospital Duran i Reynals — Barcelona, Spain
- MD Anderson Cancer Center — Madrid, Spain
- Hospital Universitario Ramon y Cajal — Madrid, Spain
- Hospital Universitario Fundacion Jimenez — Madrid, Spain
- Hospital Universitario HM Sanchinarro — Madrid, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.